Analysts at Goldman Sachs have a positive view on the strategy outlined by Royal Bank of Scotland alongside its third-quarter results. However, the group's new target for common Tier-1 equity, of over 12% versus over 10% before, means that there is now reduced upside potential in RBS shares, "towar
Read moreBroker Panmure Gordon downgraded GlaxoSmithKline after its heart drug Darapaldib, 'the great white hope in the pipeline', failed to reach its primary end-point in a late-stage trial. Analyst Savvas Neophytou trimmed his forecasts, mainly assuming a £150m writedown in the fourth quarter even though
Read moreNov 12 (Reuters) - Sarepta Therapeutics Inc said the U.S. Food and Drug Administration had raised concerns about the trial for the company's experimental muscle disorder drug and considered the marketing application for the treatment to be premature. Sarepta shares fell 39 percent to $22.20
Read more* Darapladib misses primary endpoint in Phase III trial * GSK says some success in secondary goals needs analysis * Expectations had been low for new type of heart medicine * Shares fall 1.2 percent By Ben Hirschler LONDON, Nov 12 (Reuters) - An experimental GlaxoSmi
Read moreAccesso: Canaccord Genuity raises target price from 680p to 770p and keeps a buy recommendation. Andor Technology: FinnCap places both its target price (prev.: 390p) and its hold recommendation under review. Babcock International: Jefferies increases target price from 1250p to 1600p retaining a bu
Read more- Markets eye inflation data - BoE Inflation Report due tomorrow - Corporate earnings come in mixed techMARK 2,636.87 -0.14% FTSE 100 6,706.83 -0.32% FTSE 250 15,395.24 -0.16% UK markets opened lower on Tuesday morning as investors refrained from building positions ahead of domestic inflation data
Read moreLONDON, Nov 12 (Reuters) - An experimental drug from GlaxoSmithKline, designed to fight heart disease in a new way, failed to meet its main goal in the first of two big late-stage clinical studies, the company said on Tuesday. Darapladib did, however, produce greater reductions in serious c
Read moreGlaxoSmithKline's heart disease drug, darapladib, has missed a key milestone in its development. The trial drug, which is designed to tackle heart problems in a totally different way to cholesterol-lowering medication, was in the first of two "pivotal" late-stage clinical studies. Patrick Vallan
Read moreCity sources predict the FTSE 100 will open around two points higher than yesterday's close of 6,728.37, tracking modest gains seen in the US last night and ahead of today's inflation figures. US markets ended slightly higher yesterday, with the Dow Jones Industrial Average hitting another record c
Read more* First Phase III trial data on darapladib due shortly * GSK sees once-daily pill as new way to fight heart disease * Analysts wary after lack of evidence in Phase II * Consensus forecasts point to $605 mln sales in 2018 * Billions of dollars upside if clinical trials succ
Read more